We generated a clinical dataset (Rajan et al., 2014) based on prostate cancer patients who had accepted androgen ablation therapy, and we found a significant decrease in PVR expression in patients after treatment (Figure 6F). This evidence concerns the gene PVR and prostate carcinoma.